Sahajanand Medical Tech IPO: Issue booked 82% on Day 2; check all category-wise details

Until 5 PM, the initial share sale of the company has received bids for 80,37,775 shares as compared to 97,50,482 shares on offer, as per exchange data.

The non-institutional investor (NII) category has been subscribed 0.51 times, while the retail individual investor (RII) segment saw a 0.82 times subscription. However, the Qualified Institutional Buyers (QIB) portion was booked 1.12 times.

The ₹475 crore IPO is a complete offer for sale (OFS) with a price band set between ₹327 and ₹344 per share. The IPO is a book-building issue.

The minimum lot size for an application is 43 shares, and the investor must apply for a minimum of 1 lot.

Ahead of its IPO, Sahajanand Medical Technologies raised ₹140 crore from anchor investors. The company allotted 40.71 lakh equity shares to anchor investors at ₹344 apiece, the upper end of the IPO price band.

Shares of the company will be listed on both the National Stock Exchange and the Bombay Stock Exchange.

Sahajanand Medical Technologies IPO Objective

The money raised from the IPO will be used towards the following objectives:

Sahajanand Medical Technologies IPO: Listing date and time

About Sahajanand Medical Technologies

Sahajanand Medical Technologies (SMT), founded in 2001, develops and manufactures high-risk Class III and Class C/D cardiovascular medical devices. Its portfolio spans vascular intervention (VI), comprising coronary stents, PTCA balloon catheters and coronary drug-coated balloons; structural heart (SH), comprising transcatheter aortic valve implantation (TAVI) systems and occluders; and other products, including own-brand renal stents, peripheral drug-coated balloons and traded products. 

The company’s operating model combines in-house R&D, integrated manufacturing, proprietary brands, clinical evidence generation and multi-channel distribution. The company marketed its products in 77 countries in FY26.

The company manufactures in-house at Hyderabad, Sachin SEZ in Surat and Nonthaburi, Thailand. It operates R&D centres in India and Thailand, supported by 156 professionals, including four consultants.